ArticleTherapeutic advances in musculoskeletal disease2025
Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care.
Article in Therapeutic advances in musculoskeletal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biosimilar biologic disease-modifying antirheumatic drugs (bDMARDs) are increasingly used in clinical practice; however, real-world evidence regarding safety outcomes is currently limited. Denmark has rapidly implemented biosimilars through nationwide mandatory switches, introducing infliximab biosimilars CT-P13 in 2015 and GP1111 in 2019. Objectives: To investigate the incidence of serious safety outcomes among Danish real-world arthritis patients (including biosimilar-to-biosimilar switchers) during the first year of infliximab biosimilar GP1111 treatment. Methods: Patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis initiating GP1111 during April 1, 2019-April 1, 2022 were identified in the nationwide DANBIO registry. Comorbidities at treatment start (=baseline) and safety outcomes (major adverse cardiac events (MACE), venous thromboembolic events (VTEs), deaths, severe allergic reactions, and serious infections) during 1-year follow-up were captured through linkage to nationwide registries by using diagnoses registered from hospital contacts. Each safety outcome was assessed separately in the overall GP1111 cohort and in five sub-cohorts (based on bDMARD treatment history). We calculated 1-year crude and age- and sex-adjusted incidence rates (IRs) of each safety outcome. Furthermore, baseline factors associated with risks were assessed in the overall cohort. Results: In total, 2132 patients initiating GP1111 treatment were included, whereof 1534 (72%) were infliximab-biosimilar-to-biosimilar switchers. For the overall cohort, adjusted IRs for MACE, VTEs, death, and allergic reactions were very low (⩽1.0/100 person-years). For serious infections, the adjusted IR was 3.2 (95% confidence interval (CI) 2.5-4.2) for the overall cohort, varying across sub-cohorts (IRs 2.1-5.6). Prior serious infection increased risk of serious infection (hazard ratio = 2.06 (95% CI 1.19-3.57), whereas other baseline factors, including biologic treatment history did not. Due to few events, similar analyses were not presented for other safety outcomes. Conclusion: This study demonstrated that 1 year of treatment with biosimilar infliximab GP1111 was safe regardless of treatment history. The rate of serious infections was comparable to originator tumor necrosis factor inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.